https://ir.evommune.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_2094dba4d31887f5c3cda4773c265127/evommune/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.evommune.com/news-events/press-releases/detail/122/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine Mon, 06 Apr 26 09:00:00 -0400 https://ir.evommune.com/news-events/press-releases/detail/122/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine https://ir.evommune.com/news-events/press-releases/detail/121/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights Thu, 05 Mar 26 16:01:00 -0500 https://ir.evommune.com/news-events/press-releases/detail/121/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights https://ir.evommune.com/news-events/press-releases/detail/120/evommune-announces-125-million-private-placement Thu, 12 Feb 26 20:30:00 -0500 https://ir.evommune.com/news-events/press-releases/detail/120/evommune-announces-125-million-private-placement https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis Tue, 10 Feb 26 07:30:00 -0500 https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis https://ir.evommune.com/news-events/press-releases/detail/118/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update Thu, 11 Dec 25 16:05:00 -0500 https://ir.evommune.com/news-events/press-releases/detail/118/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update https://ir.evommune.com/news-events/press-releases/detail/117/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Fri, 07 Nov 25 16:05:00 -0500 https://ir.evommune.com/news-events/press-releases/detail/117/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares https://ir.evommune.com/news-events/press-releases/detail/116/evommune-announces-pricing-of-its-initial-public-offering Wed, 05 Nov 25 19:45:00 -0500 https://ir.evommune.com/news-events/press-releases/detail/116/evommune-announces-pricing-of-its-initial-public-offering https://ir.evommune.com/news-events/press-releases/detail/115/evommune-announces-commencement-of-initial-public-offering Thu, 30 Oct 25 06:30:00 -0400 https://ir.evommune.com/news-events/press-releases/detail/115/evommune-announces-commencement-of-initial-public-offering https://ir.evommune.com/news-events/press-releases/detail/85/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress Fri, 19 Sep 25 08:30:00 -0400 https://ir.evommune.com/news-events/press-releases/detail/85/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress https://ir.evommune.com/news-events/press-releases/detail/86/evommune-announces-late-breaker-presentation-of-phase-2-data-for-evo756-in-chronic-inducible-urticaria-at-upcoming-european-academy-of-dermatology-and-venereology-eadv-2025-congress Tue, 02 Sep 25 09:30:00 -0400 https://ir.evommune.com/news-events/press-releases/detail/86/evommune-announces-late-breaker-presentation-of-phase-2-data-for-evo756-in-chronic-inducible-urticaria-at-upcoming-european-academy-of-dermatology-and-venereology-eadv-2025-congress